ABVX
Abivax
Stock NASDAQ – Stock Market Prices, News & Analysis
Abivax développe des traitements pharmaceutiques pour les maladies inflammatoires, virales et immuno-oncologiques.
Abivax
ABVX
Abivax développe des traitements pharmaceutiques pour les maladies inflammatoires, virales et immuno-oncologiques.
Price history of Abivax
Price history of Abivax
Performance & Momentum
Abivax Soars 1700% in 2025 on Strong Clinical Results
Abivax, listed on NASDAQ under the ticker ABVX, delivered an outstanding 1742% gain in 2025, driven by positive clinical data and renewed analyst confidence. Its inclusion in the Nasdaq Biotechnology Index boosted the stock's appeal. Brokerages like Piper Sandler and Guggenheim have raised their price targets, expecting significant upside potential around the obefazimod treatment. While this momentum creates a favorable environment for investors, caution is advised due to biotech sector volatility.
Similar stocks to Abivax
Recent News
Abivax
Abivax Unveils 22 Obefazimod Studies; Strong Q3 2025
2 months agoAbivax announces acceptance of 22 abstracts evaluating obefazimod for chronic inflammatory bowel diseases, including an oral presentation on preclinical anti-fibrotic results at the ECCO 2026 congress. Additionally, the company reported Q3 2025 results, showing a cash position of €589.7 million, providing financial visibility through Q4 2027. These scientific advances strengthen Abivax's position in the rapidly growing innovative ulcerative colitis treatment market, likely boosting investor interest.
Abivax Shares Jump 57% in 90 Days on Strong Outlook
3 months agoAbivax's stock surged 57% over the past three months, driven by renewed investor interest and impressive annual revenue growth. This momentum is further supported by Zacks' recent buy rating highlighting the company's promising earnings prospects. These positive factors, alongside a booming biotech sector, could sustain Abivax's stock performance in the near term.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
